{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:21:10Z","timestamp":1791523270637,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T00:00:00Z","timestamp":1576713600000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"crossref","award":["ANR-11-LABEX-0018-01"],"award-info":[{"award-number":["ANR-11-LABEX-0018-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"crossref","award":["ANR-11- LABX-0016-01"],"award-info":[{"award-number":["ANR-11- LABX-0016-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"crossref","award":["ANR-11-EQPX-0004"],"award-info":[{"award-number":["ANR-11-EQPX-0004"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"crossref","award":["ANR-16-IDEX-0007"],"award-info":[{"award-number":["ANR-16-IDEX-0007"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Diacetyl-bis(N4-methylthiosemicarbazone), labeled with 64Cu (<jats:sup>64<\/jats:sup>Cu-ATSM) has been suggested as a promising tracer for imaging hypoxia. However, various controversial studies highlighted potential pitfalls that may disable its use as a selective hypoxic marker. They also highlighted that the results may be tumor location dependent. Here, we first analyzed uptake of Cu-ATSM and its less lipophilic counterpart Cu-Cl<jats:sub>2<\/jats:sub> in the tumor over time in an orthotopic glioblastoma model. An in vitro study was also conducted to investigate the hypoxia-dependent copper uptake in tumor cells. We then further performed a comprehensive ex vivo study to compare <jats:sup>64<\/jats:sup>Cu uptake to hypoxic markers, specific cellular reactions, and also transporter expression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>\u03bcPET was performed 14\u2009days (<jats:sup>18<\/jats:sup>F-FMISO), 15\u2009days (<jats:sup>64<\/jats:sup>Cu-ATSM and <jats:sup>64<\/jats:sup>Cu-Cl2), and 16\u2009days (<jats:sup>64<\/jats:sup>Cu-ATSM and <jats:sup>64<\/jats:sup>Cu-Cl<jats:sub>2<\/jats:sub>) after C6 cell inoculation. Thereafter, the brains were withdrawn for further autoradiography and immunohistochemistry. C6 cells were also grown in hypoxic workstation to analyze cellular uptake of Cu complexes in different oxygen levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In vivo results showed that Cu-ASTM and Cu-Cl2 accumulated in hypoxic areas of the tumors. Cu-ATSM also stained, to a lesser extent, non-hypoxic regions, such as regions of astrogliosis, with high expression of copper transporters and in particular DMT-1 and CTR1, and also characterized by the expression of elevated astrogliosis. In vitro results show that 64Cu-ATSM showed an increase in the uptake only in severe hypoxia at 0.5 and 0.2% of oxygen while for <jats:sup>64<\/jats:sup>Cu-Cl2, the cell retention was significantly increased at 5% and 1% of oxygen with no significant rise at lower oxygen percentages.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In the present study, we show that Cu-complexes undoubtedly accumulate in hypoxic areas of the tumors. This uptake may be the reflection of a direct dependency to a redox metabolism and also a reflection of hypoxic-induced overexpression of transporters. We also show that Cu-ATSM also stained non-hypoxic regions such as astrogliosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13550-019-0586-6","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T19:08:03Z","timestamp":1576782483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["64Cu-ATSM\/64Cu-Cl2 and their relationship to hypoxia in glioblastoma: a preclinical study"],"prefix":"10.1186","volume":"9","author":[{"given":"Elodie A.","family":"P\u00e9r\u00e8s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Toutain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis-Paul","family":"Paty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Divoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9ziane","family":"Ibaziz\u00e8ne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Guillouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Barr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Cherel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micka\u00ebl","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Bernaudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0355-0270","authenticated-orcid":false,"given":"Samuel","family":"Valable","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,19]]},"reference":[{"key":"586_CR1","doi-asserted-by":"publisher","first-page":"10210","DOI":"10.1038\/s41598-017-08646-y","volume":"7","author":"A Chakhoyan","year":"2017","unstructured":"Chakhoyan A, Guillamo J-S, Collet S, Kauffmann F, Delcroix N, Lechapt-Zalcman E, et al. FMISO-PET-derived brain oxygen tension maps: application to glioblastoma and less aggressive gliomas. Sci Rep. 2017;7:10210.","journal-title":"Sci Rep."},{"key":"586_CR2","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/0008-5472.CAN-03-2424","volume":"64","author":"SM Evans","year":"2004","unstructured":"Evans SM, Judy KD, Dunphy I, Jenkins WT, Nelson PT, Collins R, et al. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res. 2004;64:1886\u201392.","journal-title":"Cancer Res."},{"key":"586_CR3","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s00259-017-3677-5","volume":"44","author":"L Bekaert","year":"2017","unstructured":"Bekaert L, Valable S, Lechapt-Zalcman E, Ponte K, Collet S, Constans J-M, et al. [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis. Eur J Nucl Med Mol Imaging. 2017;44:1383\u201392.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"586_CR4","first-page":"22073","volume":"8","author":"Q Liu","year":"2015","unstructured":"Liu Q, Cao P. Clinical and prognostic significance of HIF-1\u03b1 in glioma patients: a meta-analysis. Int J Clin Exp Med. 2015;8:22073\u201383.","journal-title":"Int J Clin Exp Med."},{"key":"586_CR5","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1259\/0007-1285-26-312-638","volume":"26","author":"LH Gray","year":"1953","unstructured":"Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26:638\u201348.","journal-title":"Br J Radiol."},{"key":"586_CR6","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1007\/s11064-011-0701-1","volume":"37","author":"CP Haar","year":"2012","unstructured":"Haar CP, Hebbar P, Wallace GC, Das A, Vandergrift WA, Smith JA, et al. Drug resistance in glioblastoma: a mini review. Neurochem Res. 2012;37:1192\u2013200.","journal-title":"Neurochem Res."},{"key":"586_CR7","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.18632\/oncotarget.2937","volume":"6","author":"EA P\u00e9r\u00e8s","year":"2015","unstructured":"P\u00e9r\u00e8s EA, G\u00e9rault AN, Valable S, Roussel S, Toutain J, Divoux D, et al. Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe. Oncotarget. 2015;6:2101\u201319.","journal-title":"Oncotarget."},{"key":"586_CR8","first-page":"76","volume":"1866","author":"C Michiels","year":"2016","unstructured":"Michiels C, Tellier C, Feron O. Cycling hypoxia: a key feature of the tumor microenvironment. Biochim Biophys Acta. 2016;1866:76\u201386.","journal-title":"Biochim Biophys Acta."},{"key":"586_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3389\/fmed.2015.00057","volume":"2","author":"A Corroyer-Dulmont","year":"2015","unstructured":"Corroyer-Dulmont A, Chakhoyan A, Collet S, Durand L, MacKenzie ET, Petit E, et al. Imaging modalities to assess oxygen status in glioblastoma. Front Med. 2015;2:57.","journal-title":"Front Med."},{"key":"586_CR10","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1177\/0271678X16671965","volume":"37","author":"S Valable","year":"2016","unstructured":"Valable S, Corroyer-Dulmont A, Chakhoyan A, Durand L, Toutain J, Divoux D, et al. Imaging of brain oxygenation with magnetic resonance imaging: a validation with positron emission tomography in the healthy and tumoural brain. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2016;37:2584\u201397.","journal-title":"J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab."},{"key":"586_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.5603\/NMR.2011.00022","volume":"14","author":"M Bourgeois","year":"2011","unstructured":"Bourgeois M, Rajerison H, Guerard F, Mougin-Degraef M, Barbet J, Michel N, et al. Contribution of [64Cu]-ATSM PET in molecular imaging of tumour hypoxia compared to classical [18F]-MISO--a selected review. Nucl Med Rev Cent East Eur. 2011;14:90\u20135.","journal-title":"Nucl Med Rev Cent East Eur."},{"key":"586_CR12","first-page":"1155","volume":"38","author":"Y Fujibayashi","year":"1997","unstructured":"Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med Off Publ Soc Nucl Med. 1997;38:1155\u201360.","journal-title":"J Nucl Med Off Publ Soc Nucl Med."},{"key":"586_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.nucmedbio.2008.06.001","volume":"35","author":"CS Dence","year":"2008","unstructured":"Dence CS, Ponde DE, Welch MJ, Lewis JS. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer. Nucl Med Biol. 2008;35:713\u201320.","journal-title":"Nucl Med Biol."},{"key":"586_CR14","first-page":"655","volume":"42","author":"JS Lewis","year":"2001","unstructured":"Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med Off Publ Soc Nucl Med. 2001;42:655\u201361.","journal-title":"J Nucl Med Off Publ Soc Nucl Med."},{"key":"586_CR15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3174\/ajnr.A3679","volume":"35","author":"K Tateishi","year":"2014","unstructured":"Tateishi K, Tateishi U, Nakanowatari S, Ohtake M, Minamimoto R, Suenaga J, et al. (62)Cu-diacetyl-bis (N(4)-methylthiosemicarbazone) PET in human gliomas: comparative study with [(18)F] fluorodeoxyglucose and L-methyl-[(11)C]methionine PET. AJNR Am J Neuroradiol. 2014;35:278\u201384.","journal-title":"AJNR Am J Neuroradiol."},{"key":"586_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s12149-018-1241-4","volume":"32","author":"A Toriihara","year":"2018","unstructured":"Toriihara A, Ohtake M, Tateishi K, Hino-Shishikura A, Yoneyama T, Kitazume Y, et al. Prognostic implications of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET\/CT in patients with glioma. Ann Nucl Med. 2018;32:264\u201371.","journal-title":"Ann Nucl Med."},{"key":"586_CR17","first-page":"515","volume":"55","author":"S Carlin","year":"2014","unstructured":"Carlin S, Zhang H, Reese M, Ramos NN, Chen Q, Ricketts S-A. A Comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers. J Nucl Med Off Publ Soc Nucl Med. 2014;55:515\u201321.","journal-title":"J Nucl Med Off Publ Soc Nucl Med."},{"key":"586_CR18","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1016\/j.ijrobp.2012.05.005","volume":"84","author":"KC McCall","year":"2012","unstructured":"McCall KC, Humm JL, Bartlett R, Reese M, Carlin S. Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia. Int J Radiat Oncol Biol Phys. 2012;84:e393\u20139.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"586_CR19","first-page":"989","volume":"47","author":"H Yuan","year":"2006","unstructured":"Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med Off Publ Soc Nucl Med. 2006;47:989\u201398.","journal-title":"J Nucl Med Off Publ Soc Nucl Med."},{"key":"586_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/BF02988502","volume":"15","author":"A Obata","year":"2001","unstructured":"Obata A, Yoshimi E, Waki A, Lewis JS, Oyama N, Welch MJ, et al. Retention mechanism of hypoxia selective nuclear imaging\/radiotherapeutic agent cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med. 2001;15:499\u2013504.","journal-title":"Ann Nucl Med."},{"key":"586_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.nucmedbio.2011.08.008","volume":"39","author":"Y Yoshii","year":"2012","unstructured":"Yoshii Y, Yoneda M, Ikawa M, Furukawa T, Kiyono Y, Mori T, et al. Radiolabeled Cu-ATSM as a novel indicator of overreduced intracellular state due to mitochondrial dysfunction: studies with mitochondrial DNA-less \u03c10 cells and cybrids carrying MELAS mitochondrial DNA mutation. Nucl Med Biol. 2012;39:177\u201385.","journal-title":"Nucl Med Biol."},{"key":"586_CR22","first-page":"7","volume":"55","author":"JLJ Dearling","year":"2014","unstructured":"Dearling JLJ, Packard AB. On the destiny of (copper) species. J Nucl Med Off Publ Soc Nucl Med. 2014;55:7\u20138.","journal-title":"J Nucl Med Off Publ Soc Nucl Med."},{"issue":"19","key":"586_CR23","doi-asserted-by":"publisher","first-page":"5890","DOI":"10.1002\/chem.200800539","volume":"14","author":"Jason\u2005P. Holland","year":"2008","unstructured":"Holland JP, Barnard PJ, Collison D, Dilworth JR, Edge R, Green JC, et al. Spectroelectrochemical and computational studies on the mechanism of hypoxia selectivity of copper radiopharmaceuticals. Chem Weinh Bergstr Ger. 2008;14:5890\u2013907.","journal-title":"Chemistry - A European Journal"},{"issue":"6","key":"586_CR24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.nucmedbio.2005.05.003","volume":"32","author":"Paul Burgman","year":"2005","unstructured":"Burgman P, O\u2019Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol. 2005;32:623\u201330.","journal-title":"Nuclear Medicine and Biology"},{"issue":"8","key":"586_CR25","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.2967\/jnumed.109.061879","volume":"50","author":"J. Liu","year":"2009","unstructured":"Liu J, Hajibeigi A, Ren G, Lin M, Siyambalapitiyage W, Liu Z, et al. Retention of the radiotracers 64Cu-ATSM and 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression. J Nucl Med Off Publ Soc Nucl Med. 2009;50:1332\u20139.","journal-title":"Journal of Nuclear Medicine"},{"issue":"1","key":"586_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/neuonc\/nos260","volume":"15","author":"Aur\u00e9lien Corroyer-Dulmont","year":"2012","unstructured":"Corroyer-Dulmont A, P\u00e9r\u00e8s EA, Petit E, Guillamo JS, Varoqueaux N, Roussel S, et al. Detection of glioblastoma response to temozolomide combined with bevacizumab based on \u03bcMRI and \u03bcPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy. Neuro Oncol. 2013;15:41-56.","journal-title":"Neuro-Oncology"},{"issue":"4","key":"586_CR27","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s00259-015-3225-0","volume":"43","author":"Aur\u00e9lien Corroyer-Dulmont","year":"2015","unstructured":"Corroyer-Dulmont A, P\u00e9r\u00e8s EA, G\u00e9rault AN, Savina A, Bouquet F, Divoux D, et al. Multimodal imaging based on MRI and PET reveals [(18)F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2016;43:682\u201394.","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"586_CR28","unstructured":"Valable S, Petit E, Roussel S, Marteau L, Toutain J, Divoux D, et al. Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model. Nucl Med Biol. 2011;38:781\u201393."},{"issue":"3","key":"586_CR29","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ijrobp.2008.10.025","volume":"73","author":"Nadeem Khan","year":"2009","unstructured":"Khan N, Li H, Hou H, Lariviere JP, Gladstone DJ, Demidenko E, et al. Tissue pO2 of orthotopic 9\u2009L and C6 gliomas and tumor-specific response to radiotherapy and hyperoxygenation. Int J Radiat Oncol Biol Phys. 2009;73:878\u201385.","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"586_CR30","doi-asserted-by":"crossref","unstructured":"Colombi\u00e9 M, Gouard S, Frindel M, Vidal A, Ch\u00e9rel M, Kraeber-Bod\u00e9r\u00e9 F, et al. Focus on the controversial aspects of (64)Cu-ATSM in tumoral hypoxia mapping by PET imaging. Front Med. 2015;2:58.","DOI":"10.3389\/fmed.2015.00058"},{"issue":"3","key":"586_CR31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2967\/jnumed.115.155663","volume":"57","author":"F. Li","year":"2015","unstructured":"Li F, J\u00f8rgensen JT, Forman J, Hansen AE, Kjaer A. 64Cu-ATSM Reflects pO2 levels in human head and neck cancer xenografts but not in colorectal cancer xenografts: comparison with 64CuCl2. J Nucl Med Off Publ Soc Nucl Med. 2016;57:437\u201343.","journal-title":"Journal of Nuclear Medicine"},{"key":"586_CR32","unstructured":"Hueting R, Kersemans V, Cornelissen B, Tredwell M, Hussien K, Christlieb M, et al. A comparison of the behavior of (64)Cu-acetate and (64)Cu-ATSM in vitro and in vivo. J Nucl Med Off Publ Soc Nucl Med. 2014;55:128\u201334."},{"issue":"6","key":"586_CR33","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.tem.2015.03.008","volume":"26","author":"Claire Legendre","year":"2015","unstructured":"Legendre C, Garcion E. Iron metabolism: a double-edged sword in the resistance of glioblastoma to therapies. Trends Endocrinol Metab TEM. 2015;26:322\u201331.","journal-title":"Trends in Endocrinology & Metabolism"},{"issue":"6","key":"586_CR34","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/jcp.22485","volume":"226","author":"Zhong-Ming Qian","year":"2011","unstructured":"Qian Z-M, Wu XM, Fan M, Yang L, Du F, Yung W-H, et al. Divalent metal transporter 1 is a hypoxia-inducible gene. J Cell Physiol. 2011;226:1596\u2013603.","journal-title":"Journal of Cellular Physiology"},{"key":"586_CR35","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.febslet.2012.05.058","volume":"586","author":"K Pourvali","year":"2012","unstructured":"Pourvali K, Matak P, Latunde-Dada GO, Solomou S, Mastrogiannaki M, Peyssonnaux C, et al. Basal expression of copper transporter 1 in intestinal epithelial cells is regulated by hypoxia-inducible factor 2\u03b1. FEBS Lett. 2012;586:2423\u20137.","journal-title":"FEBS Lett."},{"key":"586_CR36","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.neuint.2012.08.017","volume":"62","author":"IF Scheiber","year":"2013","unstructured":"Scheiber IF, Dringen R. Astrocyte functions in the copper homeostasis of the brain. Neurochem Int. 2013;62:556\u201365.","journal-title":"Neurochem Int."},{"key":"586_CR37","doi-asserted-by":"publisher","first-page":"L3","DOI":"10.1186\/2193-1801-4-S1-L3","volume":"4","author":"R Dringen","year":"2015","unstructured":"Dringen R, Scheiber I, Bulcke F. Copper metabolism of astrocytes. SpringerPlus. 2015;4:L3.","journal-title":"SpringerPlus."},{"key":"586_CR38","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.nucmedbio.2013.01.002","volume":"40","author":"JT J\u00f8rgensen","year":"2013","unstructured":"J\u00f8rgensen JT, Persson M, Madsen J, Kj\u00e6r A. High tumor uptake of (64)Cu: implications for molecular imaging of tumor characteristics with copper-based PET tracers. Nucl Med Biol. 2013;40:345\u201350.","journal-title":"Nucl Med Biol."},{"key":"586_CR39","first-page":"1692","volume":"55","author":"KI Kim","year":"2014","unstructured":"Kim KI, Jang SJ, Park JH, Lee YJ, Lee TS, Woo KS, et al. Detection of increased 64Cu uptake by human copper transporter 1 gene overexpression using PET with 64CuCl2 in human breast cancer xenograft model. J Nucl Med Off Publ Soc Nucl Med. 2014;55:1692\u20138.","journal-title":"J Nucl Med Off Publ Soc Nucl Med."},{"key":"586_CR40","first-page":"622","volume":"55","author":"H Cai","year":"2014","unstructured":"Cai H, Wu J, Muzik O, Hsieh J-T, Lee RJ, Peng F. Reduced 64Cu uptake and tumor growth inhibition by knockdown of human copper transporter 1 in xenograft mouse model of prostate cancer. J Nucl Med Off Publ Soc Nucl Med. 2014;55:622\u20138.","journal-title":"J Nucl Med Off Publ Soc Nucl Med."},{"key":"586_CR41","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3945\/an.110.000273","volume":"2","author":"Y Wang","year":"2011","unstructured":"Wang Y, Hodgkinson V, Zhu S, Weisman GA, Petris MJ. Advances in the understanding of mammalian copper transporters. Adv Nutr Bethesda Md. 2011;2:129\u201337.","journal-title":"Adv Nutr Bethesda Md."},{"key":"586_CR42","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/0006-291X(86)91036-3","volume":"135","author":"SH Laurie","year":"1986","unstructured":"Laurie SH, Pratt DE. Copper-albumin: what is its functional role? Biochem Biophys Res Commun. 1986;135:1064\u20138.","journal-title":"Biochem Biophys Res Commun."},{"key":"586_CR43","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1039\/C6MT00103C","volume":"8","author":"MC Linder","year":"2016","unstructured":"Linder MC. Ceruloplasmin and other copper binding components of blood plasma and their functions: an update. Met Integr Biometal Sci. 2016;8:887\u2013905.","journal-title":"Met Integr Biometal Sci."},{"key":"586_CR44","doi-asserted-by":"publisher","first-page":"e86996","DOI":"10.1371\/journal.pone.0086996","volume":"9","author":"Y Yoshii","year":"2014","unstructured":"Yoshii Y, Matsumoto H, Yoshimoto M, Furukawa T, Morokoshi Y, Sogawa C, et al. Controlled administration of penicillamine reduces radiation exposure in critical organs during 64Cu-ATSM internal radiotherapy: a novel strategy for liver protection. PloS One. 2014;9:e86996.","journal-title":"PloS One."},{"key":"586_CR45","doi-asserted-by":"publisher","first-page":"129764","DOI":"10.1155\/2015\/129764","volume":"2015","author":"C Ferrari","year":"2015","unstructured":"Ferrari C, Asabella AN, Villano C, Giacobbi B, Coccetti D, Panichelli P, et al. Copper-64 dichloride as theranostic agent for glioblastoma multiforme: a preclinical study. BioMed Res Int. 2015;2015:129764.","journal-title":"BioMed Res Int."},{"key":"586_CR46","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.tranon.2017.10.006","volume":"11","author":"Y Yoshii","year":"2018","unstructured":"Yoshii Y, Matsumoto H, Yoshimoto M, Zhang M-R, Oe Y, Kurihara H, et al. Multiple administrations of 64Cu-ATSM as a novel therapeutic option for glioblastoma: a translational study using mice with xenografts. Transl Oncol. 2018;11:24\u201330.","journal-title":"Transl Oncol."}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-019-0586-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13550-019-0586-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-019-0586-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:06:39Z","timestamp":1608249999000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-019-0586-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["586"],"URL":"https:\/\/doi.org\/10.1186\/s13550-019-0586-6","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"19 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal investigations were performed under the current European directive (2010\/63\/EU) in authorized laboratories (B14118001) and with the permission of the regional committee on animal ethics (CENOMEXA, APAFIS#1247).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}